Developing differentiated therapeutics for the treatment and prevention of falls and movement disorders

The prevention of falls among the elderly and Parkinson’s patients with movement disorders is a critical unmet medical need

Neurocea is developing a proprietary, first-in-class, Phase 3-ready oral drug to prevent falls in Parkinson’s Disease patients.

25% of adults

over the age of 65 experience at least one fall per year

61% of patients

with Parkinson’s experience an average of 21 falls per year

Falls are #1

on the list of causes for traumatic brain injury

$65 billion+

is the annual cost of hospitalization, medical & nursing care related to falls

1Bergen G, Stevens MR, Burns ER. Falls and Fall Injuries Among Adults Aged ≥65 Years — United States, 2014. MMWR Morbidity and Mortality Weekly Report.
2016;65(37):993-998. doi:10.15585/mmwr.mm6537a2

2Allen NE, Schwarzel AK, Canning CG. Recurrent Falls in Parkinson’s Disease: A Systematic Review. Parkinsons Disease.
2013;2013:1-16. doi:10.1155/2013/906274

3Jager TE, Weiss HB, Coben JH, Pepe PE. Traumatic Brain Injuries Evaluated in U.S. Emergency Departments, 1992-1994. Academic Emergency Medicine.
2000;7(2):134-140. doi:10.1111/j.1553-2712.2000.tb00515.x

4Important Facts about Falls. Centers for Disease Control and Prevention. Published February 10, 2017. Accessed June 18, 2020.


A Silicon Valley, privately-held biopharmaceutical company

Developing differentiated therapeutics for the treatment and prevention of falls and other movement disorders. Neurocea’s lead compound is NP002, a Phase 3-ready proprietary formulation of nicotine.


We’re seeking partners

We are currently seeking partners to support the development and commercialization of NP002.

Thank you.

Your message has been sent.
We will follow up shortly.